{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:44:16Z","timestamp":1785411856331,"version":"3.56.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T00:00:00Z","timestamp":1711152000000},"content-version":"vor","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015883","name":"Sociedad Espa\u00f1ola de Nefrolog\u00eda","doi-asserted-by":"publisher","award":["17PSJ026"],"award-info":[{"award-number":["17PSJ026"]}],"id":[{"id":"10.13039\/100015883","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005774","name":"Universitat de Barcelona","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005774","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.nefroe.2024.03.019","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T14:07:52Z","timestamp":1712930872000},"page":"204-216","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Tools for a personalized tacrolimus dose adjustment in the follow-up of renal transplant recipients. Metabolizing phenotype according to CYP3A genetic polymorphisms versus concentration-dose ratio"],"prefix":"10.1016","volume":"44","author":[{"given":"Anna","family":"Vidal-Alabr\u00f3","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Colom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pere","family":"Fontova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Cerezo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Melilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Coloma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Manonelles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Fav\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep M.","family":"Cruzado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Torras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep M.","family":"Griny\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Lloberas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.nefroe.2024.03.019_bib0005","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00003088-200443100-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation","volume":"43","author":"Staatz","year":"2004","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.nefroe.2024.03.019_bib0010","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/FTD.0b013e31819c3d6d","article-title":"Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients","volume":"31","author":"Press","year":"2009","journal-title":"Ther Drug Monit"},{"issue":"3","key":"10.1016\/j.nefroe.2024.03.019_bib0015","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","article-title":"Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report","volume":"41","author":"Brunet","year":"2019","journal-title":"Ther Drug Monit"},{"issue":"2","key":"10.1016\/j.nefroe.2024.03.019_bib0020","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40262-013-0120-3","article-title":"The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation","volume":"53","author":"Hesselink","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.nefroe.2024.03.019_bib0025","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1097\/FTD.0000000000000255","article-title":"Pharmacogenetic biomarkers predictive of the pharmacokinetics and pharmacodynamics of immunosuppressive drugs","volume":"38","author":"Picard","year":"2016","journal-title":"Ther Drug Monit"},{"issue":"1","key":"10.1016\/j.nefroe.2024.03.019_bib0030","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2217\/pgs.12.187","article-title":"CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy","volume":"14","author":"Elens","year":"2013","journal-title":"Pharmacogenomics"},{"issue":"7","key":"10.1016\/j.nefroe.2024.03.019_bib0035","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s40262-020-00955-2","article-title":"Clinical impact of the adaptation of initial tacrolimus dosing to the CYP3A5 genotype after kidney transplantation: systematic review and meta-analysis of randomized controlled trials","volume":"60","author":"Yang","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.nefroe.2024.03.019_bib0040","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/tri.12194","article-title":"Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation","volume":"26","author":"Asberg","year":"2013","journal-title":"Transplant Int"},{"issue":"9","key":"10.1016\/j.nefroe.2024.03.019_bib0045","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/FPC.0000000000000296","article-title":"The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation","volume":"27","author":"Lloberas","year":"2017","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.nefroe.2024.03.019_bib0050","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3389\/fphar.2017.00358","article-title":"Tacrolimus updated guidelines through popPK modeling: how to benefit more from CYP3A pre-emptive genotyping prior to kidney transplantation","volume":"8","author":"Woillard","year":"2017","journal-title":"Front Pharmacol"},{"issue":"8","key":"10.1016\/j.nefroe.2024.03.019_bib0055","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s40262-016-0491-3","article-title":"A new CYP3A5*3 and CYP3A4*22 cluster influencing tacrolimus target concentrations: a population approach","volume":"56","author":"Andreu","year":"2017","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"10.1016\/j.nefroe.2024.03.019_bib0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0111128","article-title":"The tacrolimus metabolism rate influences renal function after kidney transplantation","volume":"9","author":"Tholking","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.nefroe.2024.03.019_bib0065","doi-asserted-by":"crossref","first-page":"167","DOI":"10.12659\/AOT.895898","article-title":"Tacrolimus concentration\/dose ratio is associated with renal function after liver transplantation","volume":"21","author":"Tholking","year":"2016","journal-title":"Ann Transplant"},{"issue":"6","key":"10.1016\/j.nefroe.2024.03.019_bib0070","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1097\/TP.0000000000002920","article-title":"The TOMATO study (Tacrolimus Metabolization in Kidney Transplantation): impact of the concentration-dose ratio on death-censored graft survival","volume":"104","author":"Jouve","year":"2020","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.nefroe.2024.03.019_bib0075","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/tri.13605","article-title":"Early postoperative calculation of the tacrolimus concentration-to-dose ratio does not predict outcomes after kidney transplantation","volume":"33","author":"Bartmann","year":"2020","journal-title":"Transplant Int"},{"issue":"5","key":"10.1016\/j.nefroe.2024.03.019_bib0080","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1159\/000502290","article-title":"Tacrolimus: influence of the posttransplant concentration\/dose ratio on kidney graft function in a two-year follow-up","volume":"44","author":"Nowicka","year":"2019","journal-title":"Kidney Blood Pressure Res"},{"issue":"8","key":"10.1016\/j.nefroe.2024.03.019_bib0085","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/phar.2300","article-title":"Tacrolimus concentration-to-dose ratios in kidney transplant recipients and relationship to clinical outcomes","volume":"39","author":"Bartlett","year":"2019","journal-title":"Pharmacotherapy"},{"issue":"9","key":"10.1016\/j.nefroe.2024.03.019_bib0090","article-title":"Role of tacrolimus C\/D ratio in the first year after pediatric liver transplantation","volume":"2","author":"Prusinskas","year":"2021","journal-title":"Front Pediatr"},{"issue":"10","key":"10.1016\/j.nefroe.2024.03.019_bib0095","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.3390\/jcm8101586","article-title":"A low tacrolimus concentration\/dose ratio increases the risk for the development of acute calcineurin inhibitor - induced nephrotoxicity","volume":"8","author":"Tholking","year":"2019","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.nefroe.2024.03.019_bib0100","doi-asserted-by":"crossref","first-page":"342","DOI":"10.2174\/1389200219666180101104159","article-title":"Tacrolimus - pharmacokinetic considerations for clinicians","volume":"19","author":"Schutte-Nutgen","year":"2018","journal-title":"Curr Drug Metab"},{"issue":"5","key":"10.1016\/j.nefroe.2024.03.019_bib0105","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3390\/jcm8050587","article-title":"Tac fast metabolizers at risk - It is time for a C\/D ratio calculation","volume":"8","author":"Schutte-Nutgen","year":"2019","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.nefroe.2024.03.019_bib0110","doi-asserted-by":"crossref","first-page":"15606","DOI":"10.1038\/s41598-021-95201-5","article-title":"Increased renal function decline in fast metabolizers using extended-release tacrolimus after kidney transplantation","volume":"11","author":"Th\u00f6lking","year":"2021","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.nefroe.2024.03.019_bib0115","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1097\/TP.0000000000002366","article-title":"A 2018 reference guide to the Banff classification of renal allograft pathology","volume":"102","author":"Roufosse","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.nefroe.2024.03.019_bib0120","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s10337-015-2981-0","article-title":"Simultaneous measurement of Cyclosporine A, Everolimus, Sirolimus and Tacrolimus concentrations in human blood by UPLC\u2013MS\/MS","volume":"78","author":"Rigo-Bonnin","year":"2015","journal-title":"Chromatographia"},{"issue":"4","key":"10.1016\/j.nefroe.2024.03.019_bib0125","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/cts.13206","article-title":"A randomized crossover study comparing different tacrolimus formulations to reduce intrapatient variability in tacrolimus exposure in kidney transplant recipients","volume":"15","author":"Bunthof","year":"2021","journal-title":"Clin Transl Sci"},{"issue":"5","key":"10.1016\/j.nefroe.2024.03.019_bib0130","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/FTD.0b013e318296045b","article-title":"Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation","volume":"35","author":"Elens","year":"2013","journal-title":"Ther Drug Monit"},{"issue":"10","key":"10.1016\/j.nefroe.2024.03.019_bib0135","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1111\/ajt.15385","article-title":"Tacrolimus troughs and genetic determinants of metabolism in kidney transplant recipients: a comparison of four ancestry groups","volume":"19","author":"Mohamed","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nefroe.2024.03.019_bib0140","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/jcpt.12523","article-title":"Tacrolimus population pharmacokinetics according to CYP3A5 genotype and clinical factors in Chinese adult kidney transplant recipients","volume":"42","author":"Zhang","year":"2017","journal-title":"J Clin Pharm Ther"},{"issue":"3","key":"10.1016\/j.nefroe.2024.03.019_bib0145","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/bcp.13838","article-title":"A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients","volume":"85","author":"Andrews","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.nefroe.2024.03.019_bib0150","first-page":"1463","article-title":"Genetic polymorphisms affecting tacrolimus metabolism and the relationship to post-transplant outcomes in kidney transplant recipients","volume":"14","author":"Cheng","year":"2021","journal-title":"Pharmgenomics Pers Med"},{"key":"10.1016\/j.nefroe.2024.03.019_bib0155","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00228-013-1584-7","article-title":"Importance of hematocrit for a tacrolimus target concentration strategy","volume":"70","author":"Storset","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.nefroe.2024.03.019_bib0160","unstructured":"Lloberas, N. Bringing a pharmacokinetic population model including pharmacogenetics into clinical practice to optimize tacrolimus dosage in renal transplantation. Ponencia presentada en: The 21th European Society of Organ Transplantation (ESOT) Congress. Septiembre de 2021; Milano, Italia."}],"container-title":["Nefrolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251424000774?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251424000774?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:40:06Z","timestamp":1785253206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2013251424000774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2013251424000774"],"URL":"https:\/\/doi.org\/10.1016\/j.nefroe.2024.03.019","relation":{},"ISSN":["2013-2514"],"issn-type":[{"value":"2013-2514","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tools for a personalized tacrolimus dose adjustment in the follow-up of renal transplant recipients. Metabolizing phenotype according to CYP3A genetic polymorphisms versus concentration-dose ratio","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefroe.2024.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.nefro.2022.12.005","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Sociedad Espa\u00f1ola de Nefrolog\u00eda.","name":"copyright","label":"Copyright"}]}}